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Abstract:
Objectives:  Recent investigations in humans and mouse models with 
lupus have revealed evidence of mitochondrial dysfunction and 
production of mitochondrial reactive oxygen species (mROS) in T cells 
and neutrophils.  This can provoke numerous cellular changes including 
oxidation of nucleic acids, proteins, lipids, and even induction of cell 
death.  We have previously observed that in T cells from lupus patients 
the increased mROS is capable of provoking oligomerization of MAVS and 
production of type I Interferon (IFN-I).  mROS in SLE neutrophils also 
promotes the formation of neutrophil extracellular traps (NETs), which 
are increased in lupus and implicated in renal damage.  As a result, in 
addition to traditional immunosuppression, more comprehensive 
treatments for lupus may also include nonimmune therapy, such as 
antioxidants. 
Methods:  Lupus-prone MRL-lpr mice were treated from weaning for 11 
weeks with the mitochondria-targeted antioxidant, MitoQ (200 M) in 
drinking water.  Mice were then assessed for ROS production in 
neutrophils, NET formation, MAVS oligomerization, serum IFN-I, 
autoantibody production, and renal function. 
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Results:  MitoQ-treated mice manifested reduced neutrophil ROS and 
NET formation, decreased MAVS oligomerization and serum IFN-I, and 
reduced immune complex formation in kidneys, despite no change in 
serum autoantibody titers. 
Conclusions:  These findings reveal the potential utility of targeting 
mROS in addition to traditional immunosuppressive therapy for lupus. 
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ABSTRACT
Objectives:  Recent investigations in humans and mouse models with lupus have revealed 
evidence of mitochondrial dysfunction and production of mitochondrial reactive oxygen species 
(mROS) in T cells and neutrophils.  This can provoke numerous cellular changes including 
oxidation of nucleic acids, proteins, lipids, and even induction of cell death.  We have previously 
observed that in T cells from lupus patients the increased mROS is capable of provoking 
oligomerization of MAVS and production of type I Interferon (IFN-I).  mROS in SLE neutrophils 
also promotes the formatio  of neutrophil extracellular traps (NETs), which are increased in 
lupus and implicated in renal damage.  As a result, in addition to traditional 
immunosuppression, more comprehensive treatments for lupus may also include nonimmune 
therapy, such as antioxidants.
Methods:  Lupus-prone MRL-lpr mice were treated from weaning for 11 weeks with the 
mitochondria-targeted antioxidant, MitoQ (200 M) in drinking water.  Mice were then 
assessed for ROS production in neutrophils, NET formation, MAVS oligomerization, serum IFN-I, 
autoantibody production, and renal function.
Results:  MitoQ-treated mice manifested reduced neutrophil ROS and NET formation, 
decreased MAVS oligomerization and serum IFN-I, and reduced immune complex formation in 
kidneys, despite no change in serum autoantibody titers.
Conclusions:  These findings reveal the potential utility of targeting mROS in addition to 
traditional immunosuppressive therapy for lupus. 
Keywords:  systemic lupus erythematosus, T cells, neutrophils, mitochondria, reactive oxygen 
species
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune syndrome 
characterized by numerous abnormalities, including various autoantibodies, the appearance of 
unusual CD4-CD8- TCR-+ cells, altered metabolism of lymphocytes, a type I Interferon (IFN-I) 
gene signature in PBMC, increased formation of neutrophil extracellular traps (NETs), and 
deposition of immunoglobulins and complement at renal glomeruli 1-10.  Each of these immune 
abnormalities may provoke different aspects of the disease, and each also may be driven by 
different environmental and genetic aberrations.  Recent work has also revealed the 
importance of nonimmune factors, such as oxidative stress, in the development of end-organ 
damage in SLE, shifting the paradigm of SLE pathogenesis from that of a disease provoked solely 
by a disturbed immune system 1 7.  Thus, fully effectively treatment of SLE may require 
inhibiting pathways in addition to those targeted by traditional immunosuppressive 
medications.  
Neutrophil activation in response to glomerular immune complexes contributes to lupus 
glomerulonephritis, in part through the production of mROS that can directly injure tissue 
through oxidation of lipids, proteins, DNA, and induction of apoptosis 11 12.  We have shown 
previously that immune complex activation of neutrophils can also lead to the formation of 
NETs, which can release oxidized genomic and mitochondrial DNA and promote the production 
of IFN-I 10 12.  Furthermore, a subset of low density granulocytes (LDG) from SLE patients has an 
enhanced capacity to form NETs in a mROS-dependent manner, and these structures have been 
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observed in the kidneys of patients with lupus nephritis as well as in other lupus-affected 
tissues 11 13.  
We have also previously observed that T lymphocytes from SLE patients manifest mitochondrial 
dysfunction as evidenced by enlarged mitochondria and elevated mROS that can induce 
oxidative damage 14.  The mROS triggers the spontaneous oligomerization of the Mitochondrial 
Antiviral Stimulator (MAVS) protein and downstream IFN-I production 15.  This was likely due in 
part to induction of cysteine disulfide bonding in the CARD domain of MAVS, since a C79F 
polymorphism of MAVS known to be associated with milder SLE 16 did not efficiently 
oligomerize nor induce IFN-I with mROS 15.  In addition, we observed that oligomerized MAVS is 
reversed in vitro in the presence of the mitochondrial antioxidant, MitoQ 15.  Consequently, 
mROS and resulting oxidative damage emerge as possible driving forces in certain aspects of 
SLE, and hence represent a target for therapy.
The process that promotes the mitochondrial abnormalities in human SLE T cells is unknown.  
Hence, we examined whether a similar phenomenon of enlarged mitochondria and 
spontaneous MAVS oligomerization might occur in any of the T cell subsets of lupus-prone 
MRL-lpr mice.  T cells in these mice accumulate in large numbers in lymphoid organs through 
dysregulated homeostatic proliferation that is enhanced in the absence of the death receptor, 
Fas (CD95) 17.  The dysregulation of T cells includes the emergence with age of an increasingly 
large proportion of polyclonal CD4-CD8- TCR-+ cells that derive from CD8+ precursors during 
homeostatic proliferation 17.   A CD4-CD8- TCR-+ subset also occurs in human SLE 3 4.  Similar 
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to human SLE T cells, the lpr CD4-CD8- TCR-+ subset also manifested enlarged mitochondria 
and spontaneous MAVS oligomerization.  We thus investigated further the ability of the 
mitochondria-targeted antioxidant MitoQ in vivo to reverse mROS and NET formation, MAVS 
oligomerization, as well as to test its therapeutic potential on lupus disease manifestations in 
MRL-lpr mice.
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METHODS
Mice  
Mice were bred and housed in the Association for Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC)-approved animal facilities of The University of Vermont 
Larner College of Medicine.  Original breeding pairs of MRL/MpJ-Faslpr (MRL-lpr) mice were 
obtained from Jackson Laboratory (Bar Harbor, ME).  All breeding and animal studies were 
conducted in accordance with the policies of The University of Vermont’s Animal Care and Use 
Committee.
MitoQ treatment  
Mice were weaned at 4 weeks and placed on either drinking water alone or 200 M MitoQ 
(MitoQ, Aukland, NZ) in drinking water.  Bottles were changed weekly.  After 11 weeks 
treatment mice were euthanized and kidneys harvested for histological analysis.  Brachial and 
axillary lymph nodes were assessed for cell number and lymphocyte subsets determined by 
flow cytometry.  Neutrophils were purified from bone marrow as previously described 10.  
Serum was obtained for autoantibodies, creatinine, and BUN.  Urine was obtained for 
creatinine measurement.
Lymphocyte preparation  
Single cell suspensions of lymph nodes were prepared in RPMI 1640 (CellGro, Corning, 
Manassas, VA) containing 25 mM Hepes, 5% v/v bovine calf serum (HyClone, Logan, UT), 5 x 10-
5 M -mercaptoethanol (Sigma, St. Louis, MO), 100 U/ml penicillin, and 100 U/ml streptomycin 
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(Life Technologies-Invitrogen)(RPMI/5% BCS).  CD8+ and CD4-CD8-TCR+ T cells were isolated 
by negative selection. Lymph node cells were incubated with the appropriate antibodies (see 
below) for 30 min on ice.  After washing, the cells were incubated by rocking with goat anti-rat 
and goat anti-mouse IgG-coated beads (Qiagen, Valencia, CA) for 45 min at 4oC.  Antibody-
coated cells were removed by magnetic depletion.  To obtain CD8+ T cells, cell suspensions 
were incubated with anti-class II (3F12), anti-CD11b (M1/70), anti-NK1.1 (PK136), anti-kappa 
(187.1), anti-CD4 (GK1.5), and anti-CD45R (B220, RA3GB2).  To isolate CD4-CD8-TCR+ T cells, 
cells were incubated with anti-class II (3F12), anti-CD11b (M1/70), anti-NK1.1 (PK136), anti-
kappa (187.1), anti-CD4 (GK1.5), and anti-CD8 (Tib105).
Antibodies and flow cytometry  
The following antibodies to murine cell surface proteins were purchased from BD Biosciences 
(San Jose, CA): APC-conjugated anti-TCR, Pacific Blue-conjugated anti-CD45R (B220). The 
following antibodies were purchased from Life Technologies-Invitrogen (Grand Island, NY): PE-
conjugated anti-CD44, PE-Texas Red-conjugated anti-CD4, PE Cy5.5-conjugated anti-CD8, Pacific 
Orange-conjugated anti-CD45. The following antibodies were purchased from Biolegend (San 
Diego, CA): Alexa 647-conjugated anti-TCR, Alexa 700-conjugated anti-CD19, and Pacific Blue-
conjugated anti-CD19.  Live Dead Fixable Blue was purchased from Life Technologies-Molecular 
Probes. Lyophilized rat IgG and hamster IgG (MP Biochemicals, Solon, OH) were resuspended in 
PBS and stored at -80oC. 
For direct staining, single cell suspensions were washed with cold (4oC) PBS and then incubated 
with Live Dead Fixable Blue Stain (Life Technologies-Molecular Probes, Eugene, OR) in PBS for 
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30 min at 4oC.  The cells were washed with cold PBS containing 1% w/v BSA fraction V (Sigma, 
St. Louis, MO) (PBS/1%BSA) and then incubated with a mixture of rat IgG and hamster IgG (50 
g/ml each) for 30 min at 4oC.  After washing, the cells were incubated with the appropriate 
antibodies in PBS/1% BSA, washed, and fixed with freshly made 1% v/v methanol-free 
formaldehyde (Ted Pella, Redding CA) in PBS/1%BSA.  Flow cytometry was performed on an 
LSRII (BD Bioscience) and the data were analyzed using FloJo software (TreeStar, Ashland OR).
Analysis of mitochondrial morphology by transmission electron microscopy  
Cells were fixed for 1 h at 65°C in 2% paraformaldehyde and 2.5% glutaraldehyde (Polysciences, 
Warrington, PA) in 100 mM sodium cacodylate buffer (pH 7.2).  Samples were washed in 
cacodylate buffer and then postfixed for 1 h in 1% osmium tetroxide (Polysciences).  Samples 
were then extensively rinsed in distilled H2O before undergoing en bloc staining for 1 h with 1% 
aqueous uranyl acetate (Ted Pella).  After several rinses in distilled H2O, the samples were 
dehydrated in a graded series of ethanol and then embedded in Eponate 12 resin (Ted Pella).  
Sections (95 nm in thickness) were cut with an Ultracut UC7 ultramicrotome (Leica 
Microsystems, Wetzlar, Germany), stained with uranyl acetate and lead citrate, and viewed on 
a JEOL 1400 transmission electron microscope (JEOL USA) equipped with an XR611 high-
resolution, 11-megapixel mid-mount charge-coupled device camera (Advanced Microscopy 
Techniques, Woburn, MA).
Semidenaturing detergent agarose gel electrophoresis for detection of MAVS oligomers  
SDD-AGE was performed according to a published protocol with minor modifications 18.  Briefly, 
mitochondria were resuspended in sample buffer [0.5x tris-borate EDTA (TBE), 10% glycerol, 2% 
Page 10 of 78
https://mc.manuscriptcentral.com/lupusscimed
Lupus Science & Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
10
SDS, and 0.0025% bromophenol blue] and loaded onto a vertical 1.5% agarose gel.  After 
electrophoresis in running buffer (1x TBE, 0.1% SDS) for 35 min with a constant voltage of 75 V 
at 4°C, proteins were transferred to PVDF membranes with a Trans-Blot Turbo Transfer System 
in preparation for Western blot analysis.  PVDF membranes were blocked in tris-buffered saline 
and 5% nonfat powdered milk and analyzed with MAVS-specific antibody (Santa Cruz 
Biotechnology, Dallas, TX).  Immunoreactive proteins were visualized with horseradish 
peroxidase–labeled conjugates (Jackson ImmunoResearch, West Grove, PA) and developed 
with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA). Chemiluminescence was detected 
and recorded with a Bio-Rad Chemidoc instrument. Densitometric measurements were 
performed in Image Lab image acquisition and analysis software (Bio-Rad).
Metabolism analysis  
Real-time analysis of extracellular acidification rates (ECAR) and oxygen consumption rates 
(OCR) were measured with the XFe96 extracellular flux analyzer (Agilent Technologies, Santa 
Clara, CA) according to the manufacturer’s specifications.  Metabolic profiles were measured 
under basal conditions in nonbuffered DMEM (Sigma) containing 25 mM glucose, 2 mM L-
glutamine, and 1 mM sodium pyruvate, in response to 1 mM oligomycin, 0.5 mM FCCP,  and 1 
mM rotenone/1 mM antimycin.  Analysis was performed with the Wave Software v2.4 or v2.6 
(Agilent Technologies, Santa Clara, CA).  
Quantification of NETs and mROS in bone marrow neutrophils  
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The isolation of bone marrow-derived neutrophils, quantification of NETs and mROS were 
performed as previously described 10.  Briefly, hindlimb marrow neutrophils were purified by 
Percoll gradient.  Cells were seeded in a 96-well plate (200,000 cells/100 l/well) in triplicates 
for each dye and allowed to form NETs in the presence of SYTOX (externalized DNA, 1 M final 
concentration), Quant-It Picogreen (total DNA  stock solution diluted 1:250) and MitoSox (200 
ng/ml) (all from Thermofisher, Waltham, MA).  Fluorescence was measured at different time 
points for each dye, at the earliest time point 485/520 (Picogreen), 1 h 510/580 (MitoSox), and 
2 h 486/520 (SYTOX), using a FLUOstar Omega BMG Labtech (Cary, NC) plate reader.  Picogreen 
measurement was used as the initial number of cells or total DNA.
Autoantibody quantification  
Serum concentrations of autoantibodies were determined using commercially available ELISA 
kits (Alpha Diagnostic International, TX).  Serum was diluted (1:125) in NSB buffer and the assay 
done following manufacturer’s instructions.
Assessment of kidney histology and function  
Renal immune complex deposition was quantified as previously described 10 using an Alexa 
fluor 594-F(ab’)2-goat anti-mouse IgG (Thermofisher, Waltham, MA) and FITC-anti-murine C3 
antibody (Immunology Consultants Laboratories, Portland, OR).  Nuclei were stained with 
Hoechst (1:500, Life Technologies, Carlsbad, CA).  For quantification, three random images were 
obtained from each stained frozen section.  The images were analyzed with Image J software 
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selecting the glomerular compartment to quantify mean pixels for each fluorescence channel 
used.  
To quantify serum creatinine and eliminate the influence of chromogens in mouse serum that 
interfere with the classic Jaffe method for creatinine detection, a HPLC assay was used as 
previously described 19.  Briefly, 5 l serum were treated with 0.5 ml acetonitrile, centrifuged at 
4oC at 13,000 x g for 20 min, and supernatants were dried by SpeedVac and resuspended in 
mobile phase (5 mM sodium acetate, pH 5.1).  Duplicates were run on a 100 x 4.1 mm PRP-
X200 column (Hamilton, Reno, NV) and isocratically eluted at 2 ml/min in an Agilent 1100 
system, with UV detection at 234 nm.  Absolute quantitation was determined with a standard 
curve of 2-50 ng creatinine (r2=0.999).
Statistical analysis  
 Statistical analyses were performed using the graphing software Prism v7 (GraphPad  Software, 
La Jolla, CA, USA). The following statistical tests were used: paired and unpaired t-test when 
comparing two conditions, one-way ANOVA with Tukey’s test for correction for multiple 
comparisons when comparing multiple conditions, and two-way ANOVA with Sidak test for 
correction for multiple comparisons when comparing multiple variables across multiple 
conditions.  All data met the assumptions of the statistical tests used and variation among the 
compared groups was similar.
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RESULTS 
MRL-lpr CD4-CD8- TCR-+ cells have enlarged mitochondria, increased oxygen consumption 
and glycolysis  
Our previous observations in human SLE T cells revealed that they manifest enlarged 
mitochondria, mROS production, and spontaneous MAVS oligomerization 5 14 15.  We thus 
examined lupus-prone MRL-lpr mouse T cells for similar features.  Initial analysis revealed that 
lpr CD8+ T cells, the precursors of the CD4-CD8- TCR-+ T cells 17 20 21 contained relatively low 
mitochondrial mass, using Mitotracker and flow cytometry, whereas the CD4-CD8- TCR-+ T 
cells had markedly higher mitochondrial mass relative to the CD8+ T cells (Fig. 1A).  Further 
analysis by electron microscopy revealed that, similar to human SLE T cells 5 14 the lpr CD4-CD8- 
TCR-+ T cells contained very large and rounded mitochondria, in contrast to the more typical 
elongated mitochondria of the CD8+ subset (Fig. 1B).  This paralleled greater rates of oxygen 
consumption and glycolysis in the CD4-CD8- TCR-+ subset, as detected by Seahorse 
extracellular flux analysis (Fig. 1C).  The increased aerobic glycolysis of CD4-CD8- TCR-+ T cells 
is consistent with the known rapid proliferation by this subset in vivo 22.  This is paralleled by 
increased spontaneous cell death of the CD4-CD8- TCR-+ T cells compared to the CD4+ and 
CD8+ T cell subsets (Fig. 1D), consistent with previous observations that high levels of glycolysis 
in T cells, including CD4-CD8- TCR-+ T cells, drives high levels of active caspase-3, rendering 
them prone to cell death 23 24.  Such increased cell death could contribute to the inflammatory 
response in these mice.
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Given these parallels between T cells from human SLE and the CD4-CD8- TCR-+ T cells of MRL-
lpr mice, we examined whether they also manifested evidence of spontaneous MAVS 
oligomerization and activation of IFN-I genes.  Indeed, the CD4-CD8- TCR-+ (B220+) subset 
contained MAVS oligomers, which were diminished in the CD4+ and CD8+ (B220-) fraction and 
nonexistent in wild-type mice (Fig. 2A).  This paralleled the upregulation of several IFN-I-
stimulated genes in the CD4-CD8- TCR-+ T cells compared to the CD8+ precursors (Fig. 2B).  
Consistent with these findings, MRL-lpr mice had higher levels of serum IFN compared to wild-
type mice (Fig. 2C).  Collectively, these findings suggest that mROS may drive MAVS 
oligomerization in lpr CD4-CD8- TCR-+ T cells as it does in human SLE.  We thus considered 
that mROS and possible oxidative damage might also drive some of the disease manifestations 
in MRL-lpr mice, and elected to treat the mice in vivo with the mitochondria-targeted 
antioxidant MitoQ.
In vivo MitoQ treatment of MRL-lpr mice reduces ROS production and NET formation by 
neutrophils  
Increased production of mROS and NET formation has been observed in neutrophils of SLE 
patients 10 11.  As NET formation in human lupus is, at least in part, driven by mROS production, 
we initially examined whether the mitochondria-targeted antioxidant, MitoQ, would reduce 
neutrophil mROS and NET formation.  MitoQ contains an antioxidant, ubiquinonol, coupled to a 
triphenylphosphonium moiety containing three phenyl groups to promote membrane 
permeabilization, combined with a central positively charged phosphorous that draws the 
compound toward negative charges.  As mitochondria are about 150-170 mV negative 
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compared to the cytosol, which is itself a further 30-60 mV negative compared to the 
extracellular environment, Mito compounds are concentrated 500-1000X in mitochondria 25-27.  
Mice were administered MitoQ (200 M) in their drinking water beginning at 4 weeks of age 
and continued for 11 weeks.  No adverse effects of MitoQ (e.g. weight, development) were 
observed in mice at this dose, consistent with other studies 27-30.  mROS production in 
neutrophils was initially examined by MitoSox fluorescence plate assay.  This revealed a 
reduction in mROS production in MitoQ-treated mice, both spontaneously and following mROS 
stimulation with the calcium ionophore, A23187 (Fig. 3A).  These findings were observed for 
both male and female MRL-lpr mice.  Consistent with these findings, NET formation was also 
reduced with MitoQ treatment.  In male mice this was statistically significant for spontaneous 
NET formation, and in females this was the case following A23187 stimulation (Fig. 3B).  
Further analysis of metabolism in the neutrophils revealed reduced oxygen consumption with 
MitoQ, both at basal levels and following stimulation of respiration with the mitochondrial 
uncoupler FCCP (respiratory capacity) (Fig. 4A).  In contrast, glycolysis was largely unchanged, 
except in the case of female mice where the glycolytic capacity, following addition of ATP 
synthetase inhibitor oligomycin, was decreased with MitoQ (Fig. 4B).  These results indicate 
that oral MitoQ modulates lupus neutrophil immunometabolism and reduces their ability to 
form NETs.
MitoQ in vivo reduces MAVS oligomerization and serum IFN-I  
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CD4-CD8- TCR-+ T cells purified from MitoQ-treated mice revealed reduced levels of MAVS 
oligomerization compared with mice receiving water only (Fig. 5A).  This was paralleled by a 
reduction in serum IFN (Fig. 5B).  In contrast to the reduction of NET formation and MAVS 
oligomerization, MitoQ treatment did not affect lymph node total cell numbers, the distribution 
of T cell subsets, including  CD4-CD8- TCR-+ T cells, or B cells (not shown), nor the titers of 
serum autoantibodies (Fig. 6) in male or female MRL-lpr mice.  This was somewhat anticipated 
as MitoQ was not expected to alter events believed to be upstream of mROS production.
Reduced renal injury with MitoQ  
MRL-lpr mice develop immune complex-mediated kidney damage with age 31 32.  MitoQ 
treatment of female mice caused a reduction of the glomerular deposition of both C3 and IgG 
(Fig. 7).  This was less apparent in male mice, but male control mice had less C3 and IgG 
deposition than female control mice, so there was a narrower window in male mice in which to 
observe a difference with MitoQ.  These findings were paralleled by increased urine excretion 
of creatinine, albeit without a change in urine albumin (Fig. 8A), and was also accompanied by a 
reduction in serum BUN and creatinine in female mice (Fig. 8B).  
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DISCUSSION
The current findings suggest that inhibiting mROS and oxidative stress can mitigate certain 
aspects of autoimmune disease and organ damage in lupus-prone MRL-lpr mice.  It has been 
appreciated for some time that T cells and neutrophils in SLE patients manifest increased levels 
of ROS 5 6, but the consequences of this on other molecular abnormalities, immune 
dysregulation, or disease manifestations remain largely unexplored.  The current findings reveal 
that the mitochondria-targeted antioxidant MitoQ  can reduce oligomerization of MAVS and 
serum IFN-I, mitigate glomerular immune complex formation, and help preserve renal function.   
The IFN-I gene signature in PBMC is one of the hallmarks of SLE 8 9, yet the mechanism is 
unclear.  The IFN-I signature may be driven in part through engulfment of dead cells by 
macrophages and dendritic cells 33.  The increased rate of cell death of neutrophils in SLE 
patients, as well as the increased cell death of CD4-CD8- TCR-+ T cells in MRL-lpr mice and 
human SLE T cells, may both contribute to the source of dead cells.  The released nucleic acids 
can trigger both ROS and IFN-I production.  This is clear from genetic deficiencies in DNA 
clearance (e.g. TREX) which lead to interferonopathies 34 35.  
Another source of ROS in human SLE comes from T cells, some of which manifest enlarged 
mitochondria 5 14.  We have shown previously that ROS can induce MAVS oligomerization and 
IFN-I production in different cell types 15.  We now observe that, similar to human SLE, 
mitochondrial enlargement and spontaneous MAVS oligomerization arises in the MRL-lpr CD4-
CD8- TCR-+  subset.  This has been attributed to an imbalance of mitochondrial biogenesis 36 
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and turnover by mitophagy 37.   Specifically, our previous studies of SLE T cells have 
demonstrated HRES-1/RAB4-mediated depletion of Drp1, a mediator of mitochondrial fission 36.  
The accumulation of mitochondria in lupus T cells is sensitive to mTOR blockade, with clinical 
benefit in patients 38 and mice 39 with SLE. 
The  CD4-CD8- TCR-+ subset, which also occurs in human SLE, including inflamed kidneys 40, 
arises from recurrent homeostatic proliferation of CD8+ precursor T cells 17 41.  CD4-CD8- TCR-
+ T cells also derive from antigen-specific CD8+ T cells in wild-type mice only when the 
antigen is presented as a self-antigen 42.  Gene expression profiling of these wild-type derived 
CD4-CD8- TCR-+ T cells has revealed upregulation of genes for PD-1, IL-17, IFN, CXCL2, and 
downregulation of CD127 43, exactly the same pattern observed in lpr CD4-CD8- TCR-+ T cells 
22.  Thus, these unusual T cells are not unique to Fas-deficient lpr mice.  These findings, in 
addition to our previous observations that T cell homeostatic proliferation also leads to the 
upregulation of genes involved with cytolysis and inflammation 22 adds further importance why 
it is critical to regulate the homeostatic expansion of T cells with Fas.   In addition to these gene 
expression changes, our findings also suggest that part of the program of dysregulated T cell 
homeostatic proliferation in lpr mice includes mitochondrial enlargement leading to mROS 
production and MAVS oligomerization.  
MitoQ has shown therapeutic potential in a variety of conditions in which mROS has been 
implicated.  These include animal models of Alzheimer’s disease 29, liver fibrosis 30, NLRP3 
inflammasome-mediated colitis 28, cardiac ischemia-reperfusion 44, and the metabolic 
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syndrome in ApoE-/- mice 27.  In human trials MitoQ prevented inflammatory damage in a phase 
II study in hepatitis C 45, showed no benefit in Parkinson’s disease but was well tolerated 46, and 
improved vascular function in older adults 47.  Oxidative stress could be functioning at several 
levels in SLE, including induction of MAVS oligomerization 15 and oxidized mitochondrial DNA 
release during NET formation 10, each contributing to the activation of the IFN-I pathway.  In 
addition, immune complex and complement deposition in renal glomeruli induces oxidative 
stress in renal epithelium 10.  Thus, MitoQ may function at several points in reducing oxidative 
damage in the pathogenesis of SLE.  
From our current understanding that MitoQ reduces mROS and oxidative stress and hence 
events downstream of mROS generation, we would not have anticipated MitoQ to affect events 
upstream of mROS production.  These might include the development of lymphadenopathy of 
MRL-lpr mice, the generation of CD4-CD8- TCR-+ T cells, and the production of 
autoantibodies, which may result from the absence of cell death occurring during homeostatic 
proliferation of lymphocytes 17 48.  Consequently, the upregulation of genes during T cell 
homeostatic proliferation involved with cytolysis and inflammation, such as Granzyme B, 
perforin, and Fas-Ligand 22, are likely to still contribute to inflammation during MitoQ therapy.  
Thus, fully effective therapy for SLE may require a combination of traditional 
immunosuppression with nonimmune antioxidant therapy.   
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FIGURE LEGENDS
Figure 1.  MRL-lpr CD4-CD8- TCR-+ cells have enlarged mitochondria and increased oxidative 
and glycolytic metabolism.  (A) Lymph node cells from MRL-lpr mice were analyzed by flow 
cytometry for expression of TCR-+, CD4, CD8, and mitochondrial mass using Mitotracker.  (B) 
Electron micrographs (12,000x) of mitochondria from MRL-lpr CD8+ or CD4-CD8- T cells.  Red bar 
insert represents 500 nm. (C) Oxygen Consumption Rate (OCR) and Extracellular Acidification 
Rate (ECAR) for freshly isolated MRL-lpr CD4+ plus CD8+ T cells or CD4-CD8- T cells determined in 
extracellular flux analyzer.  Shown are means +/-SEM of 5 replicates of each subset.  (D) 
Spontaneous cell death following a 2 h incubation in complete medium at 37oC.  Findings and 
means +/- SEM for three experiments normalized to death rate of CD4+ plus CD8+ subset.   
Results are representative of three experiments.  Statistical analysis was by unpaired t-test.  
Figure 2.  MRL-lpr CD4-CD8- TCR-+ cells manifest spontaneously oligomerized MAVS and 
increased expression of IFN-I-stimulated genes (ISG) and serum IFN-I.  (A) Lymph node cells 
from MRL-lpr mice were separated into CD4-CD8- TCR-+ (DN) and CD4+ plus CD8+ (B220-) 
subsets and cell lysates prepared.  Comparisons were made with lymph node cells from MRL+/+ 
wild-type (WT) or MAVS-KO mice.  Lysates were subjected to 1% agarose gels (upper panel) to 
selectively visualize MAVS oligomers, or SDS-PAGE (lower panel) to visualize total MAVS 
monomer levels.  (B) Fold increase in RNA expression for several ISG comparing female MRL-lpr 
DN to naïve CD8+CD44low cells of the same mice.  RNA was hybridized to Affymetrix GeneChip 
Mouse 430 2.0.  Results are from five untreated 10-week old mice per experiment and 
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performed three times.  (C) Serum levels of IFN-I in female MRL+/+ wild-type (WT) and MRL-lpr 
mice.  Shown are the mean +/- SEM of 5 mice of each type.  Statistical analysis was by unpaired 
t-test.  Results were very similar in three experiments.
Figure 3.  In vivo MitoQ treatment reduces levels of ROS and NET formation in neutrophils.  
Mice (8 mice per treatment group) were administered either drinking water alone, or water 
containing MitoQ (200 M) for 11 weeks following weaning.  Neutrophils were purified from 
bone marrow and assayed for (A) ROS production and (B) NET formation either spontaneously 
or following activation with A23187.  Percent control refers to the comparison of each value to 
the mean of female neutrophils with A23187 activation.  Shown are points for individual mice 
and their mean for three experiments.  Statistical analysis was unpaired t-test.  
Figure 4.  Reduced oxygen consumption and glycolysis following in vivo MitoQ treatment.  
Extracellular flux analysis for (A) oxygen consumption rate (OCR) and (B) glycolysis as measured 
by extracellular acidification rate (ECAR) for neutrophils from mice (6 mice per group, 2 
experiments) administered water alone or MitoQ (200 M) in drinking water.  Shown are mean 
and statistical analysis by unpaired t-test.  Results are representative of three experiments.
Figure 5.  Reduced MAVS oligomerization and serum IFN with MitoQ.  (A) MAVS oligomers 
were assessed by Western blot from non-denaturing agarose gels as described in the Materials 
and Methods.  Shown are results from 5 mice per treatment group.  Graphs indicate density of 
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MAVS oligomers.  (B) Serum IFN as measured by ELISA.  Shown are mean +/-SEM and 
statistical analysis by unpaired t-test.  Results are representative of two experiments.
Figure 6.  MitoQ does not alter autoantibody titers in MRL-lpr mice.  MRL-lpr mice received 
water only or water containing MitoQ for 11 weeks.  Serum autoantibody titers were measured 
by ELISA.  Results shown are the combined findings of three experiments normalized to the 
water-only controls.  Numbers of MRL-lpr mice in each treatment group (N=H20/MitoQ)were: 
males ANA (N=13/14), males beta-2 glycoprotein 1 (N=9/9), males cardiolipin (N=10/9), females 
ANA (N=18/22), females beta-2 glycoprotein 1 (N=10/13), females cardiolipin (N=10/13).
Figure 7.  MitoQ reduces kidney immune complexes in female mice.  Kidneys were stained for 
C3 (green), IgG (red), and nuclei by Hoechst stain (blue) and imaged by fluorescence 
microscopy.  The glomerular-associated fluorescence was analyzed by pixel quantification in 
each fluorescence channel using Image J.  An example is shown in (A) and summaries of all mice 
analyzed is shown in (B).  
Figure 8. MitoQ improves renal function in female mice.  Urine and serum were collected from 
mice at the end of 11 weeks on water alone or water containing MitoQ.  (A) Urine creatinine 
and albumin concentrations were measured as detailed in the Material and Methods.  (B) 
Serum BUN and creatinine concentrations were determined as in the Materials and Methods.  
Results show mean and individual values for 8-10 mice in each treatment group and of each 
sex.  Statistical analysis was unpaired t-test.  Results are representative of two experiments.  
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Key Messages
What is already known about this subject?
 Murine and human SLE manifest evidence of mitochondrial dysfunction and increased 
ROS in T cells and neutrophils, with increased NET formation.
What does this study add?
 Using a lupus-prone MRL-lpr mice, this study demonstrates that the accumulating CD4-
CD8- TCR-+ subset, which is also increased in human SLE, manifests enlarged 
mitochondria and MAVS spontaneous oligomerization.
 As the CD4-CD8- TCR-+ subset arises from homeostatic proliferation, it suggests that 
the mitochondrial abnormalities in SLE T cells arise from increased homeostatic 
proliferation.
 Administration of the mitochondria-targeted antioxidant, MitoQ, to MRL-lpr mice 
reduces neutrophil ROS and NET formation, MAVS oligomerization in T cells, serum IFN-
I, and renal immune complex deposition.
How might this impact on clinical practice or future developments?
 The findings demonstrate that part of the abnormalities in SLE reflect mitochondrial 
abnormalities that contribute to the type I IFN signature of SLE, and that mitochondria-
targeted antioxidants like MitoQ may provide a useful therapeutic addition to 
traditional immunosuppressive therapy.
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Running Title: MitoQ reduces NETs and kidney disease in MRL-lpr mice
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ABSTRACT
Objectives:  Recent investigations in humans and mouse models with lupus have revealed 
evidence of mitochondrial dysfunction and production of mitochondrial reactive oxygen species 
(mROS) in T cells and neutrophils.  This can provoke numerous cellular changes including 
oxidation of nucleic acids, proteins, lipids, and even induction of cell death.  We have previously 
observed that in T cells from lupus patients the increased mROS is capable of provoking 
oligomerization of MAVS and production of type I Interferon (IFN-I).  mROS in SLE neutrophils 
also promotes the formatio  of neutrophil extracellular traps (NETs), which are increased in 
lupus and implicated in renal damage.  As a result, in addition to traditional 
immunosuppression, more comprehensive treatments for lupus may also include nonimmune 
therapy, such as antioxidants.
Methods:  Lupus-prone MRL-lpr mice were treated from weaning for 11 weeks with the 
mitochondria-targeted antioxidant, MitoQ (200 M) in drinking water.  Mice were then 
assessed for ROS production in neutrophils, NET formation, MAVS oligomerization, serum IFN-I, 
autoantibody production, and renal function.
Results:  MitoQ-treated mice manifested reduced neutrophil ROS and NET formation, 
decreased MAVS oligomerization and serum IFN-I, and reduced immune complex formation in 
kidneys, despite no change in serum autoantibody titers.
Conclusions:  These findings reveal the potential utility of targeting mROS in addition to 
traditional immunosuppressive therapy for lupus. 
Keywords:  systemic lupus erythematosus, T cells, neutrophils, mitochondria, reactive oxygen 
species
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4
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune syndrome 
characterized by numerous abnormalities, including various autoantibodies, the appearance of 
unusual CD4-CD8- TCR-+ cells, altered metabolism of lymphocytes, a type I Interferon (IFN-I) 
gene signature in PBMC, increased formation of neutrophil extracellular traps (NETs), and 
deposition of immunoglobulins and complement at renal glomeruli 1-10.  Each of these immune 
abnormalities may provoke different aspects of the disease, and each also may be driven by 
different environmental and genetic aberrations.  Recent work has also revealed the 
importance of nonimmune factors, such as oxidative stress, in the development of end-organ 
damage in SLE, shifting the paradigm of SLE pathogenesis from that of a disease provoked solely 
by a disturbed immune system 1 7.  Thus, fully effectively treatment of SLE may require 
inhibiting pathways in addition to those targeted by traditional immunosuppressive 
medications.  
Neutrophil activation in response to glomerular immune complexes contributes to lupus 
glomerulonephritis, in part through the production of mROS that can directly injure tissue 
through oxidation of lipids, proteins, DNA, and induction of apoptosis 11 12.  We have shown 
previously that immune complex activation of neutrophils can also lead to the formation of 
NETs, which can release oxidized genomic and mitochondrial DNA and promote the production 
of IFN-I 10 12.  Furthermore, a subset of low density granulocytes (LDG) from SLE patients has an 
enhanced capacity to form NETs in a mROS-dependent manner, and these structures have been 
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5
observed in the kidneys of patients with lupus nephritis as well as in other lupus-affected 
tissues 11 13.  
We have also previously observed that T lymphocytes from SLE patients manifest mitochondrial 
dysfunction as evidenced by enlarged mitochondria and elevated mROS that can induce 
oxidative damage 14.  The mROS triggers the spontaneous oligomerization of the Mitochondrial 
Antiviral Stimulator (MAVS) protein and downstream IFN-I production 15.  This was likely due in 
part to induction of cysteine disulfide bonding in the CARD domain of MAVS, since a C79F 
polymorphism of MAVS known to be associated with milder SLE 16 did not efficiently 
oligomerize nor induce IFN-I with mROS 15.  In addition, we observed that oligomerized MAVS is 
reversed in vitro in the presence of the mitochondrial antioxidant, MitoQ 15.  Consequently, 
mROS and resulting oxidative damage emerge as possible driving forces in certain aspects of 
SLE, and hence represent a target for therapy.
The process that promotes the mitochondrial abnormalities in human SLE T cells is unknown.  
Hence, we examined whether a similar phenomenon of enlarged mitochondria and 
spontaneous MAVS oligomerization might occur in any of the T cell subsets of lupus-prone 
MRL-lpr mice.  T cells in these mice accumulate in large numbers in lymphoid organs through 
dysregulated homeostatic proliferation that is enhanced in the absence of the death receptor, 
Fas (CD95) 17.  The dysregulation of T cells includes the emergence with age of an increasingly 
large proportion of polyclonal CD4-CD8- TCR-+ cells that derive from CD8+ precursors during 
homeostatic proliferation 17.   A CD4-CD8- TCR-+ subset also occurs in human SLE 3 4.  Similar 
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6
to human SLE T cells, the lpr CD4-CD8- TCR-+ subset also manifested enlarged mitochondria 
and spontaneous MAVS oligomerization.  We thus investigated further the ability of the 
mitochondria-targeted antioxidant MitoQ in vivo to reverse mROS and NET formation, MAVS 
oligomerization, as well as to test its therapeutic potential on lupus disease manifestations in 
MRL-lpr mice.
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METHODS
Mice  
Mice were bred and housed in the Association for Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC)-approved animal facilities of The University of Vermont 
Larner College of Medicine.  Original breeding pairs of MRL/MpJ-Faslpr (MRL-lpr) mice were 
obtained from Jackson Laboratory (Bar Harbor, ME).  All breeding and animal studies were 
conducted in accordance with the policies of The University of Vermont’s Animal Care and Use 
Committee.
MitoQ treatment  
Mice were weaned at 4 weeks and placed on either drinking water alone or 200 M MitoQ 
(MitoQ, Aukland, NZ) in drinking water.  Bottles were changed weekly.  After 11 weeks 
treatment mice were euthanized and kidneys harvested for histological analysis.  Brachial and 
axillary lymph nodes were assessed for cell number and lymphocyte subsets determined by 
flow cytometry.  Neutrophils were purified from bone marrow as previously described 10.  
Serum was obtained for autoantibodies, creatinine, and BUN.  Urine was obtained for 
creatinine measurement.
Lymphocyte preparation  
Single cell suspensions of lymph nodes were prepared in RPMI 1640 (CellGro, Corning, 
Manassas, VA) containing 25 mM Hepes, 5% v/v bovine calf serum (HyClone, Logan, UT), 5 x 10-
5 M -mercaptoethanol (Sigma, St. Louis, MO), 100 U/ml penicillin, and 100 U/ml streptomycin 
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8
(Life Technologies-Invitrogen)(RPMI/5% BCS).  CD8+ and CD4-CD8-TCR+ T cells were isolated 
by negative selection. Lymph node cells were incubated with the appropriate antibodies (see 
below) for 30 min on ice.  After washing, the cells were incubated by rocking with goat anti-rat 
and goat anti-mouse IgG-coated beads (Qiagen, Valencia, CA) for 45 min at 4oC.  Antibody-
coated cells were removed by magnetic depletion.  To obtain CD8+ T cells, cell suspensions 
were incubated with anti-class II (3F12), anti-CD11b (M1/70), anti-NK1.1 (PK136), anti-kappa 
(187.1), anti-CD4 (GK1.5), and anti-CD45R (B220, RA3GB2).  To isolate CD4-CD8-TCR+ T cells, 
cells were incubated with anti-class II (3F12), anti-CD11b (M1/70), anti-NK1.1 (PK136), anti-
kappa (187.1), anti-CD4 (GK1.5), and anti-CD8 (Tib105).
Antibodies and flow cytometry  
The following antibodies to murine cell surface proteins were purchased from BD Biosciences 
(San Jose, CA): APC-conjugated anti-TCR, Pacific Blue-conjugated anti-CD45R (B220). The 
following antibodies were purchased from Life Technologies-Invitrogen (Grand Island, NY): PE-
conjugated anti-CD44, PE-Texas Red-conjugated anti-CD4, PE Cy5.5-conjugated anti-CD8, Pacific 
Orange-conjugated anti-CD45. The following antibodies were purchased from Biolegend (San 
Diego, CA): Alexa 647-conjugated anti-TCR, Alexa 700-conjugated anti-CD19, and Pacific Blue-
conjugated anti-CD19.  Live Dead Fixable Blue was purchased from Life Technologies-Molecular 
Probes. Lyophilized rat IgG and hamster IgG (MP Biochemicals, Solon, OH) were resuspended in 
PBS and stored at -80oC. 
For direct staining, single cell suspensions were washed with cold (4oC) PBS and then incubated 
with Live Dead Fixable Blue Stain (Life Technologies-Molecular Probes, Eugene, OR) in PBS for 
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9
30 min at 4oC.  The cells were washed with cold PBS containing 1% w/v BSA fraction V (Sigma, 
St. Louis, MO) (PBS/1%BSA) and then incubated with a mixture of rat IgG and hamster IgG (50 
g/ml each) for 30 min at 4oC.  After washing, the cells were incubated with the appropriate 
antibodies in PBS/1% BSA, washed, and fixed with freshly made 1% v/v methanol-free 
formaldehyde (Ted Pella, Redding CA) in PBS/1%BSA.  Flow cytometry was performed on an 
LSRII (BD Bioscience) and the data were analyzed using FloJo software (TreeStar, Ashland OR).
Analysis of mitochondrial morphology by transmission electron microscopy  
Cells were fixed for 1 h at 65°C in 2% paraformaldehyde and 2.5% glutaraldehyde (Polysciences, 
Warrington, PA) in 100 mM sodium cacodylate buffer (pH 7.2).  Samples were washed in 
cacodylate buffer and then postfixed for 1 h in 1% osmium tetroxide (Polysciences).  Samples 
were then extensively rinsed in distilled H2O before undergoing en bloc staining for 1 h with 1% 
aqueous uranyl acetate (Ted Pella).  After several rinses in distilled H2O, the samples were 
dehydrated in a graded series of ethanol and then embedded in Eponate 12 resin (Ted Pella).  
Sections (95 nm in thickness) were cut with an Ultracut UC7 ultramicrotome (Leica 
Microsystems, Wetzlar, Germany), stained with uranyl acetate and lead citrate, and viewed on 
a JEOL 1400 transmission electron microscope (JEOL USA) equipped with an XR611 high-
resolution, 11-megapixel mid-mount charge-coupled device camera (Advanced Microscopy 
Techniques, Woburn, MA).
Semidenaturing detergent agarose gel electrophoresis for detection of MAVS oligomers  
SDD-AGE was performed according to a published protocol with minor modifications 18.  Briefly, 
mitochondria were resuspended in sample buffer [0.5x tris-borate EDTA (TBE), 10% glycerol, 2% 
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10
SDS, and 0.0025% bromophenol blue] and loaded onto a vertical 1.5% agarose gel.  After 
electrophoresis in running buffer (1x TBE, 0.1% SDS) for 35 min with a constant voltage of 75 V 
at 4°C, proteins were transferred to PVDF membranes with a Trans-Blot Turbo Transfer System 
in preparation for Western blot analysis.  PVDF membranes were blocked in tris-buffered saline 
and 5% nonfat powdered milk and analyzed with MAVS-specific antibody (Santa Cruz 
Biotechnology, Dallas, TX).  Immunoreactive proteins were visualized with horseradish 
peroxidase–labeled conjugates (Jackson ImmunoResearch, West Grove, PA) and developed 
with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA). Chemiluminescence was detected 
and recorded with a Bio-Rad Chemidoc instrument. Densitometric measurements were 
performed in Image Lab image acquisition and analysis software (Bio-Rad).
Metabolism analysis  
Real-time analysis of extracellular acidification rates (ECAR) and oxygen consumption rates 
(OCR) were measured with the XFe96 extracellular flux analyzer (Agilent Technologies, Santa 
Clara, CA) according to the manufacturer’s specifications.  Metabolic profiles were measured 
under basal conditions in nonbuffered DMEM (Sigma) containing 25 mM glucose, 2 mM L-
glutamine, and 1 mM sodium pyruvate, in response to 1 mM oligomycin, 0.5 mM FCCP,  and 1 
mM rotenone/1 mM antimycin.  Analysis was performed with the Wave Software v2.4 or v2.6 
(Agilent Technologies, Santa Clara, CA).  
Quantification of NETs and mROS in bone marrow neutrophils  
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11
The isolation of bone marrow-derived neutrophils, quantification of NETs and mROS were 
performed as previously described 10.  Briefly, hindlimb marrow neutrophils were purified by 
Percoll gradient.  Cells were seeded in a 96-well plate (200,000 cells/100 l/well) in triplicates 
for each dye and allowed to form NETs in the presence of SYTOX (externalized DNA, 1 M final 
concentration), Quant-It Picogreen (total DNA  stock solution diluted 1:250) and MitoSox (200 
ng/ml) (all from Thermofisher, Waltham, MA).  Fluorescence was measured at different time 
points for each dye, at the earliest time point 485/520 (Picogreen), 1 h 510/580 (MitoSox), and 
2 h 486/520 (SYTOX), using a FLUOstar Omega BMG Labtech (Cary, NC) plate reader.  Picogreen 
measurement was used as the initial number of cells or total DNA.
Autoantibody quantification  
Serum concentrations of autoantibodies were determined using commercially available ELISA 
kits (Alpha Diagnostic International, TX).  Serum was diluted (1:125) in NSB buffer and the assay 
done following manufacturer’s instructions.
Assessment of kidney histology and function  
Renal immune complex deposition was quantified as previously described 10 using an Alexa 
fluor 594-F(ab’)2-goat anti-mouse IgG (Thermofisher, Waltham, MA) and FITC-anti-murine C3 
antibody (Immunology Consultants Laboratories, Portland, OR).  Nuclei were stained with 
Hoechst (1:500, Life Technologies, Carlsbad, CA).  For quantification, three random images were 
obtained from each stained frozen section.  The images were analyzed with Image J software 
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12
selecting the glomerular compartment to quantify mean pixels for each fluorescence channel 
used.  
To quantify serum creatinine and eliminate the influence of chromogens in mouse serum that 
interfere with the classic Jaffe method for creatinine detection, a HPLC assay was used as 
previously described 19.  Briefly, 5 l serum were treated with 0.5 ml acetonitrile, centrifuged at 
4oC at 13,000 x g for 20 min, and supernatants were dried by SpeedVac and resuspended in 
mobile phase (5 mM sodium acetate, pH 5.1).  Duplicates were run on a 100 x 4.1 mm PRP-
X200 column (Hamilton, Reno, NV) and isocratically eluted at 2 ml/min in an Agilent 1100 
system, with UV detection at 234 nm.  Absolute quantitation was determined with a standard 
curve of 2-50 ng creatinine (r2=0.999).
Statistical analysis  
 Statistical analyses were performed using the graphing software Prism v7 (GraphPad  Software, 
La Jolla, CA, USA). The following statistical tests were used: paired and unpaired t-test when 
comparing two conditions, one-way ANOVA with Tukey’s test for correction for multiple 
comparisons when comparing multiple conditions, and two-way ANOVA with Sidak test for 
correction for multiple comparisons when comparing multiple variables across multiple 
conditions.  All data met the assumptions of the statistical tests used and variation among the 
compared groups was similar.
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RESULTS 
MRL-lpr CD4-CD8- TCR-+ cells have enlarged mitochondria, increased oxygen consumption 
and glycolysis  
Our previous observations in human SLE T cells revealed that they manifest enlarged 
mitochondria, mROS production, and spontaneous MAVS oligomerization 5 14 15.  We thus 
examined lupus-prone MRL-lpr mouse T cells for similar features.  Initial analysis revealed that 
lpr CD8+ T cells, the precursors of the CD4-CD8- TCR-+ T cells 17 20 21 contained relatively low 
mitochondrial mass, using Mitotracker and flow cytometry, whereas the CD4-CD8- TCR-+ T 
cells had markedly higher mitochondrial mass relative to the CD8+ T cells (Fig. 1A).  Further 
analysis by electron microscopy revealed that, similar to human SLE T cells 5 14 the lpr CD4-CD8- 
TCR-+ T cells contained very large and rounded mitochondria, in contrast to the more typical 
elongated mitochondria of the CD8+ subset (Fig. 1B).  This paralleled greater rates of oxygen 
consumption and glycolysis in the CD4-CD8- TCR-+ subset, as detected by Seahorse 
extracellular flux analysis (Fig. 1C).  The increased aerobic glycolysis of CD4-CD8- TCR-+ T cells 
is consistent with the known rapid proliferation by this subset in vivo 22.  This is paralleled by 
increased spontaneous cell death of the CD4-CD8- TCR-+ T cells compared to the CD4+ and 
CD8+ T cell subsets (Fig. 1D), consistent with previous observations that high levels of glycolysis 
in T cells, including CD4-CD8- TCR-+ T cells, drives high levels of active caspase-3, rendering 
them prone to cell death 23 24.  Such increased cell death could contribute to the inflammatory 
response in these mice.
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Given these parallels between T cells from human SLE and the CD4-CD8- TCR-+ T cells of MRL-
lpr mice, we examined whether they also manifested evidence of spontaneous MAVS 
oligomerization and activation of IFN-I genes.  Indeed, the CD4-CD8- TCR-+ (B220+) subset 
contained MAVS oligomers, which were diminished in the CD4+ and CD8+ (B220-) fraction and 
nonexistent in wild-type mice (Fig. 2A).  This paralleled the upregulation of several IFN-I-
stimulated genes in the CD4-CD8- TCR-+ T cells compared to the CD8+ precursors (Fig. 2B).  
Consistent with these findings, MRL-lpr mice had higher levels of serum IFN compared to wild-
type mice (Fig. 2C).  Collectively, these findings suggest that mROS may drive MAVS 
oligomerization in lpr CD4-CD8- TCR-+ T cells as it does in human SLE.  We thus considered 
that mROS and possible oxidative damage might also drive some of the disease manifestations 
in MRL-lpr mice, and elected to treat the mice in vivo with the mitochondria-targeted 
antioxidant MitoQ.
In vivo MitoQ treatment of MRL-lpr mice reduces ROS production and NET formation by 
neutrophils  
Increased production of mROS and NET formation has been observed in neutrophils of SLE 
patients 10 11.  As NET formation in human lupus is, at least in part, driven by mROS production, 
we initially examined whether the mitochondria-targeted antioxidant, MitoQ, would reduce 
neutrophil mROS and NET formation.  MitoQ contains an antioxidant, ubiquinonol, coupled to a 
triphenylphosphonium moiety containing three phenyl groups to promote membrane 
permeabilization, combined with a central positively charged phosphorous that draws the 
compound toward negative charges.  As mitochondria are about 150-170 mV negative 
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compared to the cytosol, which is itself a further 30-60 mV negative compared to the 
extracellular environment, Mito compounds are concentrated 500-1000X in mitochondria 25-27.  
Mice were administered MitoQ (200 M) in their drinking water beginning at 4 weeks of age 
and continued for 11 weeks.  No adverse effects of MitoQ (e.g. weight, development) were 
observed in mice at this dose, consistent with other studies 27-30.  mROS production in 
neutrophils was initially examined by MitoSox fluorescence plate assay.  This revealed a 
reduction in mROS production in MitoQ-treated mice, both spontaneously and following mROS 
stimulation with the calcium ionophore, A23187 (Fig. 3A).  These findings were observed for 
both male and female MRL-lpr mice.  Consistent with these findings, NET formation was also 
reduced with MitoQ treatment.  In male mice this was statistically significant for spontaneous 
NET formation, and in females this was the case following A23187 stimulation (Fig. 3B).  
Further analysis of metabolism in the neutrophils revealed reduced oxygen consumption with 
MitoQ, both at basal levels and following stimulation of respiration with the mitochondrial 
uncoupler FCCP (respiratory capacity) (Fig. 4A).  In contrast, glycolysis was largely unchanged, 
except in the case of female mice where the glycolytic capacity, following addition of ATP 
synthetase inhibitor oligomycin, was decreased with MitoQ (Fig. 4B).  These results indicate 
that oral MitoQ modulates lupus neutrophil immunometabolism and reduces their ability to 
form NETs.
MitoQ in vivo reduces MAVS oligomerization and serum IFN-I  
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16
CD4-CD8- TCR-+ T cells purified from MitoQ-treated mice revealed reduced levels of MAVS 
oligomerization compared with mice receiving water only (Fig. 5A).  This was paralleled by a 
reduction in serum IFN (Fig. 5B).  In contrast to the reduction of NET formation and MAVS 
oligomerization, MitoQ treatment did not affect lymph node total cell numbers, the distribution 
of T cell subsets, including  CD4-CD8- TCR-+ T cells, or B cells (not shown), nor the titers of 
serum autoantibodies (Fig. 6) in male or female MRL-lpr mice.  This was somewhat anticipated 
as MitoQ was not expected to alter events believed to be upstream of mROS production.
Reduced renal injury with MitoQ  
MRL-lpr mice develop immune complex-mediated kidney damage with age 31 32.  MitoQ 
treatment of female mice caused a reduction of the glomerular deposition of both C3 and IgG 
(Fig. 7).  This was less apparent in male mice, but male control mice had less C3 and IgG 
deposition than female control mice, so there was a narrower window in male mice in which to 
observe a difference with MitoQ.  These findings were paralleled by increased urine excretion 
of creatinine, albeit without a change in urine albumin (Fig. 8A), and was also accompanied by a 
reduction in serum BUN and creatinine in female mice (Fig. 8B).  
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DISCUSSION
The current findings suggest that inhibiting mROS and oxidative stress can mitigate certain 
aspects of autoimmune disease and organ damage in lupus-prone MRL-lpr mice.  It has been 
appreciated for some time that T cells and neutrophils in SLE patients manifest increased levels 
of ROS 5 6, but the consequences of this on other molecular abnormalities, immune 
dysregulation, or disease manifestations remain largely unexplored.  The current findings reveal 
that the mitochondria-targeted antioxidant MitoQ  can reduce oligomerization of MAVS and 
serum IFN-I, mitigate glomerular immune complex formation, and help preserve renal function.   
The IFN-I gene signature in PBMC is one of the hallmarks of SLE 8 9, yet the mechanism is 
unclear.  The IFN-I signature may be driven in part through engulfment of dead cells by 
macrophages and dendritic cells 33.  The increased rate of cell death of neutrophils in SLE 
patients, as well as the increased cell death of CD4-CD8- TCR-+ T cells in MRL-lpr mice and 
human SLE T cells, may both contribute to the source of dead cells.  The released nucleic acids 
can trigger both ROS and IFN-I production.  This is clear from genetic deficiencies in DNA 
clearance (e.g. TREX) which lead to interferonopathies 34 35.  
Another source of ROS in human SLE comes from T cells, some of which manifest enlarged 
mitochondria 5 14.  We have shown previously that ROS can induce MAVS oligomerization and 
IFN-I production in different cell types 15.  We now observe that, similar to human SLE, 
mitochondrial enlargement and spontaneous MAVS oligomerization arises in the MRL-lpr CD4-
CD8- TCR-+  subset.  This has been attributed to an imbalance of mitochondrial biogenesis 36 
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and turnover by mitophagy 37.   Specifically, our previous studies of SLE T cells have 
demonstrated HRES-1/RAB4-mediated depletion of Drp1, a mediator of mitochondrial fission 36.  
The accumulation of mitochondria in lupus T cells is sensitive to mTOR blockade, with clinical 
benefit in patients 38 and mice 39 with SLE. 
The  CD4-CD8- TCR-+ subset, which also occurs in human SLE, including inflamed kidneys 40, 
arises from recurrent homeostatic proliferation of CD8+ precursor T cells 17 41.  CD4-CD8- TCR-
+ T cells also derive from antigen-specific CD8+ T cells in wild-type mice only when the 
antigen is presented as a self-antigen 42.  Gene expression profiling of these wild-type derived 
CD4-CD8- TCR-+ T cells has revealed upregulation of genes for PD-1, IL-17, IFN, CXCL2, and 
downregulation of CD127 43, exactly the same pattern observed in lpr CD4-CD8- TCR-+ T cells 
22.  Thus, these unusual T cells are not unique to Fas-deficient lpr mice.  These findings, in 
addition to our previous observations that T cell homeostatic proliferation also leads to the 
upregulation of genes involved with cytolysis and inflammation 22 adds further importance why 
it is critical to regulate the homeostatic expansion of T cells with Fas.   In addition to these gene 
expression changes, our findings also This suggests that part of the program of dysregulated T 
cell homeostatic proliferation in lpr mice includes mitochondrial enlargement leading to mROS 
production and MAVS oligomerization.  These findings, in addition to our previous observations 
that T cell homeostatic proliferation also leads to the upregulation of genes involved with 
cytolysis and inflammation 22 adds further importance why it is critical to regulate the 
homeostatic expansion of T cells with Fas.   
Page 62 of 78
https://mc.manuscriptcentral.com/lupusscimed
Lupus Science & Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
19
MitoQ has shown therapeutic potential in a variety of conditions in which mROS has been 
implicated.  These include animal models of Alzheimer’s disease 29, liver fibrosis 30, NLRP3 
inflammasome-mediated colitis 28, cardiac ischemia-reperfusion 44, and the metabolic 
syndrome in ApoE-/- mice 27.  In human trials MitoQ prevented inflammatory damage in a phase 
II study in hepatitis C 45, showed no benefit in Parkinson’s disease but was well tolerated 46, and 
improved vascular function in older adults 47.  Oxidative stress could be functioning at several 
levels in SLE, including induction of MAVS oligomerization 15 and oxidized mitochondrial DNA 
release during NET formatio  10, each contributing to the activation of the IFN-I pathway.  In 
addition, immune complex and complement deposition in renal glomeruli induces oxidative 
stress in renal epithelium 10.  Thus, MitoQ may function at several points in reducing oxidative 
damage in the pathogenesis of SLE.  
From our current understanding that MitoQ reduces mROS and oxidative stress and hence 
events downstream of mROS generationthis, we would not have anticipated MitoQ to affect 
events upstream of mROS production.  These might include the development of 
lymphadenopathy of MRL-lpr mice, the generation of CD4-CD8- TCR-+ T cells, and the 
production of autoantibodies, which may result from the absence of cell death occurring during 
homeostatic proliferation of lymphocytes 17 48.  Consequently, the upregulation of genes during 
T cell homeostatic proliferation involved with cytolysis and inflammation, such as Granzyme B, 
perforin, and Fas-Ligand 22, are likely to still contribute to inflammation during MitoQ therapy.  
Thus, fully effective therapy for SLE may require a combination of traditional 
immunosuppression with nonimmune antioxidant therapy.   
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FIGURE LEGENDS
Figure 1.  MRL-lpr CD4-CD8- TCR-+ cells have enlarged mitochondria and increased oxidative 
and glycolytic metabolism.  (A) Lymph node cells from MRL-lpr mice were analyzed by flow 
cytometry for expression of TCR-+, CD4, CD8, and mitochondrial mass using Mitotracker.  (B) 
Electron micrographs (12,000x) of mitochondria from MRL-lpr CD8+ or CD4-CD8- T cells.  Red bar 
insert represents 500 nm. (C) Oxygen Consumption Rate (OCR) and Extracellular Acidification 
Rate (ECAR) for freshly isolated MRL-lpr CD4+ plus CD8+ T cells or CD4-CD8- T cells determined in 
extracellular flux analyzer.  Shown are means +/-SEM of 5 replicates of each subset.  (D) 
Spontaneous cell death following a 2 h incubation in complete medium at 37oC.  Findings and 
means +/- SEM for three experiments normalized to death rate of CD4+ plus CD8+ subset.   
Results are representative of three experiments.  Statistical analysis was by unpaired t-test.  
Figure 2.  MRL-lpr CD4-CD8- TCR-+ cells manifest spontaneously oligomerized MAVS and 
increased expression of IFN-I-stimulated genes (ISG) and serum IFN-I.  (A) Lymph node cells 
from MRL-lpr mice were separated into CD4-CD8- TCR-+ (DN) and CD4+ plus CD8+ (B220-) 
subsets and cell lysates prepared.  Comparisons were made with lymph node cells from MRL+/+ 
wild-type (WT) or MAVS-KO mice.  Lysates were subjected to 1% agarose gels (upper panel) to 
selectively visualize MAVS oligomers, or SDS-PAGE (lower panel) to visualize total MAVS 
monomer levels.  (B) Fold increase in RNA expression for several ISG comparing female MRL-lpr 
DN to naïve CD8+CD44low cells of the same mice.  RNA was hybridized to Affymetrix GeneChip 
Mouse 430 2.0.  Results are from five untreated 10-week old mice per experiment and 
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performed three times.  (C) Serum levels of IFN-I in female MRL+/+ wild-type (WT) and MRL-lpr 
mice.  Shown are the mean +/- SEM of 5 mice of each type.  Statistical analysis was by unpaired 
t-test.  Results were very similar in three experiments.
Figure 3.  In vivo MitoQ treatment reduces levels of ROS and NET formation in neutrophils.  
Mice (8 mice per treatment group) were administered either drinking water alone, or water 
containing MitoQ (200 M) for 11 weeks following weaning.  Neutrophils were purified from 
bone marrow and assayed for (A) ROS production and (B) NET formation either spontaneously 
or following activation with A23187.  Percent control refers to the comparison of each value to 
the mean of female neutrophils with A23187 activation.  Shown are points for individual mice 
and theirare mean +/-SEM for three experiments.  Statistical analysis was unpaired t-test.  
Figure 4.  Reduced oxygen consumption and glycolysis following in vivo MitoQ treatment.  
Extracellular flux analysis for (A) oxygen consumption rate (OCR) and (B) glycolysis as measured 
by extracellular acidification rate (ECAR) for neutrophils from mice (6 mice per group, 2 
experiments) administered water alone or MitoQ (200 M) in drinking water.  Shown are mean 
+/-SEM and statistical analysis by unpaired t-test.  Results are representative of three 
experiments.
Figure 5.  Reduced MAVS oligomerization and serum IFN with MitoQ.  (A) MAVS oligomers 
were assessed by Western blot from non-denaturing agarose gels as described in the Materials 
and Methods.  Shown are results from 5 mice per treatment group.  Graphs indicate density of 
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MAVS oligomers.  (B) Serum IFN as measured by ELISA.  Shown are mean +/-SEM and 
statistical analysis by unpaired t-test.  Results are representative of two experiments.
Figure 6.  MitoQ does not alter autoantibody titers in MRL-lpr mice.  MRL-lpr mice received 
water only or water containing MitoQ for 11 weeks.  Serum autoantibody titers were measured 
by ELISA.  Results shown are the combined findings are representative of three experiments. 
normalized to the water-only controls.  Numbers of MRL-lpr mice in each treatment group 
(N=H20/MitoQ)were: males ANA (N=13/14), males beta-2 glycoprotein 1 (N=9/9), males 
cardiolipin (N=10/9), females ANA (N=18/22), females beta-2 glycoprotein 1 (N=10/13), females 
cardiolipin (N=10/13).
Figure 7.  MitoQ reduces kidney immune complexes in female mice.  Kidneys were stained for 
C3 (green), IgG (red), and nuclei by Hoechst stain (blue) and imaged by fluorescence 
microscopy.  The glomerular-associated fluorescence was analyzed by pixel quantification in 
each fluorescence channel using Image J.  An example is shown in (A) and summaries of all mice 
analyzed is shown in (B).  
Figure 8. MitoQ improves renal function in female mice.  Urine and serum were collected from 
mice at the end of 11 weeks on water alone or water containing MitoQ.  (A) Urine creatinine 
and albumin concentrations were measured as detailed in the Material and Methods.  (B) 
Serum BUN and creatinine concentrations were determined as in the Materials and Methods.  
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Results show mean and individual values for 8-10 mice in each treatment group and of each 
sex.  Statistical analysis was unpaired t-test.  Results are representative of two experiments.  
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Key Messages
What is already known about this subject?
 Murine and human SLE manifest evidence of mitochondrial dysfunction and increased 
ROS in T cells and neutrophils, with increased NET formation.
What does this study add?
 Using a lupus-prone MRL-lpr mice, this study demonstrates that the accumulating CD4-
CD8- TCR-+ subset, which is also increased in human SLE, manifests enlarged 
mitochondria and MAVS spontaneous oligomerization.
 As the CD4-CD8- TCR-+ subset arises from homeostatic proliferation, it suggests that 
the mitochondrial abnormalities in SLE T cells arise from increased homeostatic 
proliferation.
 Administration of the mitochondria-targeted antioxidant, MitoQ, to MRL-lpr mice 
reduces neutrophil ROS and NET formation, MAVS oligomerization in T cells, serum IFN-
I, and renal immune complex deposition.
How might this impact on clinical practice or future developments?
 The findings demonstrate that part of the abnormalities in SLE reflect mitochondrial 
abnormalities that contribute to the type I IFN signature of SLE, and that mitochondria-
targeted antioxidants like MitoQ may provide a useful therapeutic addition to 
traditional immunosuppressive therapy.
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